SCHEMBL6337645

SCHEMBL6337645

CC(=O)N(Oc1ccccc1)c1c[c]ccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
TSHR P16473 2/20 0.37
TSPO P30536 1/20 0.36
MTNR1A P48039 3/20 0.35
MTNR1B P49286 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HTT P42858 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
ALDH1A1 P00352 2/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622873 0.83 ATM (0.47) ATMTDP1L3MBTL1KMT2AMEN1
SCHEMBL5461840 0.82 TSPO (0.38) ATMTDP1L3MBTL1KMT2AMEN1
SCHEMBL1419451 0.82 MEN1 (0.33) KMT2AMEN1TSHRMTNR1AMTNR1B
SCHEMBL6333714 0.78 TSHR (0.33) TSHRSMN1; SMN2ALDH1A1GLA
SCHEMBL5462369 0.75 ALOX5 (0.41) KMT2AMEN1TSHRMTNR1AMTNR1B
SCHEMBL27539918 0.74 CRHBP (0.40) KMT2AMEN1TSHRMTNR1AMTNR1B
SCHEMBL4581584 0.73 ATM (0.32) ATMTDP1L3MBTL1
SCHEMBL2235493 0.73 SMN1; SMN2 (0.42) KMT2ATSPOHTTNPC1RAB9A
SCHEMBL27825318 0.71
SCHEMBL10784052 0.70 ATM (0.48) ATMTDP1L3MBTL1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6967197-B2 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-22 US claimed
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 US claimed
US-6967197-B2 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-22 US disclosed
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors MMP9, MMP1, MMP3 ATM 3660/4885TDP1 3418/4885L3MBTL1 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.